The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.00
Bid: 43.50
Ask: 44.50
Change: -1.70 (-3.80%)
Spread: 1.00 (2.299%)
Open: 45.00
High: 45.25
Low: 43.00
Prev. Close: 44.70
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta plans fundraise to fund clinical development

Wed, 28th Feb 2024 20:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Issues trading update to December 31. Expects 2023 revenue of EUR13.4 million, nearly three times 2022's EUR4.8 million. But, predicts adjusted loss before interest, tax, depreciation and amortisation widens to EUR4.1 million from EUR2.0 million. Says this reflects expenses made in the development of artificial intelligence products, costs associated with the listing of classes A and B shares into the Access segment of the AQSE Growth Market, and the acquisition of companies.

----------

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Plans to raise GBP13.8 million via placing and subscription at 50 pence per share. In addition, proposes to raise further GBP6.2 million via a conditional placing and GBP6.8 million by a retail offer. Proceeds to be used to initiate and progress the dose expansion and Phase 2 efficacy studies for its lead pre|CISIONTM clinical programme, AVA6000, as well as for general working capital until the end of 2025.

----------

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Receives conversion notice on February 20 from Macquarie Bank Ltd for GBP80,000 of convertible bonds from the GBP5.0 million convertible bond facility announced on January 25. Further, plans to seek alternative financing options for its inorganic acquisition strategy, rather than drawing upon the facility any further.

----------

Beacon Rise Holdings PLC - acquisition company - Notes resolution at today's emergency general meeting was backed by 100% of shareholders. Explains vote extends time frame for Beacon Rise to pursue a suitable acquisition target for a further 12 months, to March 24, 2025.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - At the general meeting held Wednesday, announces the ordinary resolution relating to the adoption of the new investment policy was duly passed by shareholders. Around 87% of shareholders supported the motion.

----------

Beacon Energy PLC - Isle of Man-registered oil and gas company - Plans to raise GBP2.6 million via placing and retail offer at 0.05 pence per share. Explains the placing will be effected by way of an accelerated bookbuild. Proceeds to be used for further drilling, payment of outstanding costs and general working capital. States cash resources at February 16 totalled EUR1.2 million. Notes due to

delays during the drilling of the SCHB-2(2.) well, the company has an outstanding payables position due to a small number of contractors. Of this, around EUR1.1 million is due prior to the end of April with the balance of around EUR1.4 million due between May and August and expected to be funded from production post side-track. Beacon Energy expects to deliver operating cash flows during 2024 of around EUR40,000, EUR300,000, EUR800,000 and EUR1.3 million per month, at flow rates of 150, 300, 600 and 900 barrels of oil per day.

----------

Asian Energy Impact Trust PLC - investment company focused on sustainable energy infrastructure projects - Notes significant minority vote at Wednesday's general meeting, just over 20%, against resolutions 1, 2 and 3. Pledges to continue to seek to engage with shareholders to discuss any views they may have and will take into account any feedback around their concerns. Vote 1 was to receive the 2022 annual report and accounts of the company. Vote 2 to approve the directors' remuneration report. Vote 3 was to approve the directors' remuneration policy.

----------

Contango Holdings PLC - Holds 70% interest in the Muchesu mine in Zimbabwe - Reports pretax loss in the six months to November 30 of GBP1.4 million, narrowed from GBP1.8 million the year prior. Basic and diluted loss per share totalled 0.27p, compared to 0.55p. Administrative fees and other expenses fall to GBP879,951 from GBP1.3 million.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more
14 Jul 2021 11:30

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Read more
14 Jul 2021 11:10

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

Read more
14 Jul 2021 09:02

Avacta gets ISO certification for Affirmer manufacture and distribution

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

Read more
29 Jun 2021 12:12

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

Read more
29 Jun 2021 11:37

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

Read more
29 Jun 2021 08:36

Avacta rapid Covid-19 test detects Delta variant in study

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.

Read more
23 Jun 2021 10:28

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

Read more
21 Jun 2021 19:24

IN BRIEF: Avacta signs distribution deal for its Covid test

IN BRIEF: Avacta signs distribution deal for its Covid test

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
21 Jun 2021 08:37

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

Read more
11 Jun 2021 12:27

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

Read more
11 Jun 2021 11:40

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

Read more
7 Jun 2021 11:31

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

Read more
7 Jun 2021 10:11

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.